Adaptive Alzheimer's Disease Treatment Systems for Specialized Environments
Legal Citation
Summary of the Inventive Concept
The inventive concept discloses novel systems and methods for treating and preventing Alzheimer's disease in specialized environments, such as high-security facilities, disaster relief areas, extreme weather conditions, isolated areas, and for patients with compromised immune systems.
Background and Problem Solved
The original patent disclosed methods for treating and preventing Alzheimer's disease using aluminum salts. However, these methods did not address the unique challenges and requirements of specific environments and patient populations. The new inventive concept addresses these limitations by providing adaptive treatment systems tailored to these niche applications.
Detailed Description of the Inventive Concept
The inventive concept comprises four main components: (1) a pharmaceutical formulation comprising an aluminum salt in an amount from about 1.0 mg to about 2.0 mg; (2) a system or method designed to operate in a specific environment, such as high-security facilities, disaster relief areas, extreme weather conditions, or isolated areas; (3) optional additional features, such as emergency response training, weather-resistant containers, or wearable devices for tracking cognitive function; and (4) a communication module for transmitting tracked data to a remote monitoring center. These components work together to provide effective treatment and prevention of Alzheimer's disease in specialized environments.
Novelty and Inventive Step
The new claims introduce novel and non-obvious adaptations of the original patent's methods to address the unique challenges of specialized environments and patient populations. The inventive concept's combination of a pharmaceutical formulation with environment-specific design elements and optional additional features constitutes a significant departure from the prior art.
Alternative Embodiments and Variations
Alternative embodiments of the inventive concept could include variations in the pharmaceutical formulation, such as different dosages or combinations of active ingredients. Additionally, the system or method could be adapted for use in other specialized environments, such as military operations or space exploration.
Potential Commercial Applications and Market
The inventive concept has significant commercial potential in the healthcare and pharmaceutical industries, particularly in the areas of geriatric care, disaster relief, and extreme environment operations. The target market includes healthcare providers, pharmaceutical companies, and government agencies responsible for disaster relief and emergency response.
Section 103 Obviousness Analysis (PHOSITA)
Field of Art
Neurological treatment and pharmaceutical compositions, specifically focused on Alzheimer's disease and cognitive impairment interventions, with expertise in pharmaceutical formulations, patient assessment, and medical device design
Person of Ordinary Skill (PHOSITA) Profile
A medical researcher or pharmaceutical scientist with advanced degrees in neuroscience or pharmacology, experienced in developing treatment protocols for neurodegenerative diseases, familiar with patient assessment techniques and environmental adaptation of medical interventions
Obviousness Rationale
A PHOSITA would recognize that the source patent's core method of administering aluminum salt for cognitive treatment naturally extends to specialized environmental contexts, as medical interventions frequently require adaptation to diverse patient populations and challenging conditions. The PTD's variations represent predictable engineering solutions that apply standard medical design principles to the existing treatment methodology. The incremental additions of environmental considerations, tracking technologies, and supplemental therapeutic approaches would be considered routine optimization strategies within the field of neurodegenerative disease management.
Obvious Combinations & Variations
Original Patent Information
| Patent Number | US 11,857,568 |
|---|---|
| Title | Treatment and prevention of Alzheimer's disease (AD) |
| Assignee(s) | Advantage Therapeutics, Inc. |